U.S. FDA Approves Breyanzi for Adults with Rel... - CLL Support
U.S. FDA Approves Breyanzi for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
You need to be a member of this community to see this post.
Read more about...
5 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jan 19,...
FDA Approves Duvelisib for CLL and Follicular Lymphoma - Sep 24, 2018
FDA Approves Duvelisib for CLL and Follicular Lymphoma
Published: Monday, Sep 24, 2018
The FDA has...
FDA Approves Venetoclax (VENCLEXTA) For CLL or SLL with or without 17p deletion, who have received at least one prior therapy
FDA Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic...
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
Related Posts
Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll
CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)- "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
- Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
